Antidiabetic bicyclic compounds

A compound of formula I, or a pharmaceutically acceptable salt thereof:

• wherein Ar is selected from the group consisting of phenyl, naphthyl, a 5-6 membered monocyclic heteroaromatic group having 1-3 heteroatoms independently selected from N, O, and S, and a benzoheteroaromatic group comprising a phenyl ring fused to a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O and S,
• wherein Ar is optionally substituted with 1-2 aromatic groups independently selected from phenyl, phenoxy, benzyl, and a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O and S and is optionally substituted with 1-5 substituents independently selected from halogen, —CN, —NO2, —OH, —C(═O)H, —C(═O)OH, C1-6alkyl, —C3-6cycloalkyl, —OC1-6alkyl, —SC1-6alkyl, —C(═O)C1-6alkyl, —OC(═O)C1-6alkyl, —C(═O)OC1-6alkyl, —S(O)2C1-6alkyl, —NR13R14, —C(═O)N(R13)(R14), —S(O)2NR13R14, and —OC3-6cycloalkyl, wherein (a) C1-6alkyl in all instances is optionally substituted with 1-5 halogens and optionally 1 group selected from —OH and —OC1-4alkyl optionally substituted with 1-5 halogens, (b) —C3-6cycloalkyl in all instances is optionally substituted with 1-2 substituents independently selected from halogen and CH3, and (c) the aromatic substituent groups phenyl, phenoxy, benzyl, and the 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O and S are optionally substituted with 1-5 groups independently selected from halogen, —CN, —NO2, —OH, —C(═O)H, —C(═O)OH, C1-6alkyl, —OC1-6alkyl, —SC1-6alkyl, —C(═O)C1-6alkyl, —OC(═O)C1-6alkyl, —C(═O)OC1-6alkyl, —S(O)2C1-6alkyl, NR13R14, —C(═O)N(R13)(R14), —S(O)2NR13R14, and —O(CH2)q(4-6 membered heterocycle having 1-2 heteroatoms independently selected from O, S and N), wherein C1-6alkyl in all instances is optionally substituted with 1-5 halogens and optionally 1 group selected from —OH and —OC1-4alkyl optionally substituted with 1-5 halogens, and the 4-6 membered heterocycle having 1-2 heteroatoms independently selected from O, S and N is optionally substituted with 1-2 groups independently selected from halogen, CH3, and CF3;
• X is selected from the group consisting of —O—, —S—, —S(O)—, —S(O)2—, —NR5—, —OCR10R11—, —SCR10R11—, —NR5CR10R11—, —CR10R11O—, —CR10R11S—, —CR10R11NR5—, and —CR6R7CR8R9O—;
• Y is selected from the group consisting of —O—, —S—, —S(O)—, —S(O)2—, —NR5—, —C(═O)—, —CR6R7—, —OCR6R7—, —SCR6R7—, and —CR6R7CR8R9—;
• Z is selected from the group consisting of —C(═O)OR12, —C(═O)NR13R14, and 5-tetrazolyl;
• R1, R2, and R3 are each independently selected from the group consisting of H, halogen, C1-3alkyl, and —OC1-3alkyl, wherein C1-3alkyl, and —OC1-3alkyl are each optionally substituted with 1-3 halogens;
• R4 is selected from the group consisting of halogen, —CN, —NO2, —OH, —C(═O)H, —C(═O)OH, C1-6alkyl, —OC1-6alkyl, —SC1-6alkyl, —C(═O)C1-6alkyl, —OC(═O)C1-6alkyl, —C(═O)OC1-6alkyl, —S(O)2C1-6alkyl, —NR13R14, —C(═O)N(R13)(R14), and —S(O)2NR13R14, wherein C1-6alkyl in all instances is optionally substituted with 1-5 halogens;
• R5, R13 and R14 are each independently selected from the group consisting of H, C1-5alkyl, —C(═O)C1-5alkyl, and —S(O)2C1-5alkyl, wherein C1-5alkyl in all instances is optionally substituted with 1-5 halogens;
• R6, R7, R8, R9, R10, and R11 are each independently selected from the group consisting of H, halogen, —OH, and C1-3alkyl which is optionally substituted with 1-5 halogens;
• R12 is selected from the group consisting of H and C1-7alkyl which is optionally substituted with 1-5 halogens;
• p is an integer from 0-3;
• and
• q is 0 or 1.